{"corpus_id":554884,"paper_sha":"4a4ba81b5a8cab7d178b242d035ca904dd5fc518","doi":"10.1158/0008-5472.CAN-05-0259","arxiv_id":null,"pmid":15930265,"pmcid":null,"mag_id":2097946794,"dblp_id":null,"acl_id":null,"title":"In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants.","year":2005,"publication_date":"2005-06-01","venue":"Cancer Research","journal":{"name":"Cancer research","pages":"\n          4500-5\n        ","volume":"65 11"},"journal_issn":null,"journal_title":null,"publication_types":["JournalArticle"],"pubmed_pub_types":["Journal Article","Research Support, N.I.H., Extramural","Research Support, Non-U.S. Gov't","Research Support, U.S. Gov't, P.H.S."],"s2_fields_of_study":["Biology","Medicine"],"reference_count":25,"citation_count":1093,"influential_citation_count":74,"is_open_access":true,"arxiv_categories":null,"arxiv_license":null,"arxiv_journal_ref":null,"mesh_headings":[{"d":"Animals","mj":false,"ui":"D000818"},{"d":"Antineoplastic Agents","mj":false,"qs":[{"q":"pharmacology","mj":false,"ui":"Q000494"}],"ui":"D000970"},{"d":"Benzamides","mj":false,"ui":"D001549"},{"d":"Cell Line","mj":false,"ui":"D002460"},{"d":"Dasatinib","mj":false,"ui":"D000069439"},{"d":"Fusion Proteins, bcr-abl","mj":false,"ui":"D016044"},{"d":"Imatinib Mesylate","mj":false,"ui":"D000068877"},{"d":"Leukemia, Myelogenous, Chronic, BCR-ABL Positive","mj":false,"qs":[{"q":"drug therapy","mj":false,"ui":"Q000188"},{"q":"enzymology","mj":false,"ui":"Q000201"}],"ui":"D015464"},{"d":"Mice","mj":false,"ui":"D051379"},{"d":"Models, Molecular","mj":false,"ui":"D008958"},{"d":"Piperazines","mj":false,"qs":[{"q":"pharmacology","mj":true,"ui":"Q000494"}],"ui":"D010879"},{"d":"Protein Kinase Inhibitors","mj":false,"qs":[{"q":"pharmacology","mj":true,"ui":"Q000494"}],"ui":"D047428"},{"d":"Protein Structure, Tertiary","mj":false,"ui":"D017434"},{"d":"Protein-Tyrosine Kinases","mj":false,"qs":[{"q":"antagonists & inhibitors","mj":true,"ui":"Q000037"},{"q":"genetics","mj":false,"ui":"Q000235"}],"ui":"D011505"},{"d":"Pyrimidines","mj":false,"qs":[{"q":"pharmacology","mj":true,"ui":"Q000494"}],"ui":"D011743"},{"d":"Thiazoles","mj":false,"qs":[{"q":"pharmacology","mj":true,"ui":"Q000494"}],"ui":"D013844"}],"chemicals":[{"n":"Antineoplastic Agents","ui":"D000970","reg":"0"},{"n":"Benzamides","ui":"D001549","reg":"0"},{"n":"Piperazines","ui":"D010879","reg":"0"},{"n":"Protein Kinase Inhibitors","ui":"D047428","reg":"0"},{"n":"Pyrimidines","ui":"D011743","reg":"0"},{"n":"Thiazoles","ui":"D013844","reg":"0"},{"n":"Imatinib Mesylate","ui":"D000068877","reg":"8A1O1M485B"},{"n":"Protein-Tyrosine Kinases","ui":"D011505","reg":"EC 2.7.10.1"},{"n":"Fusion Proteins, bcr-abl","ui":"D016044","reg":"EC 2.7.10.2"},{"n":"nilotinib","ui":"C498826","reg":"F41401512X"},{"n":"Dasatinib","ui":"D000069439","reg":"RBZ1571X5H"}],"comments_corrections":null,"source_flags":5,"s2_open_access_pdf_url":"https://aacr.figshare.com/articles/journal_contribution/Supplementary_Figure_1_from_i_In_vitro_i_Activity_of_Bcr-Abl_Inhibitors_AMN107_and_BMS-354825_against_Clinically_Relevant_Imatinib-Resistant_Abl_Kinase_Domain_Mutants/22363796/1/files/39808019.pdf","s2_open_access_landing_url":"https://www.semanticscholar.org/paper/4a4ba81b5a8cab7d178b242d035ca904dd5fc518","s2_open_access_license":"CCBY","s2_open_access_status":"GREEN","pmc_open_access_pdf_url":null,"pmc_open_access_landing_url":null,"pmc_open_access_license":null,"pmc_open_access_status":null,"unpaywall_open_access_pdf_url":null,"unpaywall_open_access_landing_url":null,"unpaywall_open_access_license":null,"unpaywall_open_access_status":null,"abstract":"Imatinib, a Bcr-Abl tyrosine kinase inhibitor, is a highly effective therapy for patients with chronic myelogenous leukemia (CML). Despite durable responses in most chronic phase patients, relapses have been observed and are much more prevalent in patients with advanced disease. The most common mechanism of acquired imatinib resistance has been traced to Bcr-Abl kinase domain mutations with decreased imatinib sensitivity. Thus, alternate Bcr-Abl kinase inhibitors that have activity against imatinib-resistant mutants would be useful for patients who relapse on imatinib therapy. Two such Bcr-Abl inhibitors are currently being evaluated in clinical trials: the improved potency, selective Abl inhibitor AMN107 and the highly potent dual Src/Abl inhibitor BMS-354825. In the current article, we compared imatinib, AMN107, and BMS-354825 in cellular and biochemical assays against a panel of 16 kinase domain mutants representing >90% of clinical isolates. We report that AMN107 and BMS-354825 are 20-fold and 325-fold more potent than imatinib against cells expressing wild-type Bcr-Abl and that similar improvements are maintained for all imatinib-resistant mutants tested, with the exception of T315I. Thus, both inhibitors hold promise for treating imatinib-refractory CML.","claims":[{"public_id":"cl_99e15348defea28da9c0733b93af1323","status":"active","text":"AMN107 and BMS-354825 are 20-fold and 325-fold more potent than imatinib against cells expressing wild-type Bcr-Abl.","confidence":0.95,"contributors":[{"id":32,"public_id":"7c402c1b98","public_label":"뀨 (7c402c1b98)","roles":["extraction"],"url":"https://sah.borca.ai/u/7c402c1b98"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_99e15348defea28da9c0733b93af1323"},{"public_id":"cl_77338944702374b0bba5f42e8675e2f8","status":"active","text":"AMN107 and BMS-354825 are being evaluated in clinical trials for treating imatinib-refractory CML.","confidence":0.9,"contributors":[{"id":32,"public_id":"7c402c1b98","public_label":"뀨 (7c402c1b98)","roles":["extraction"],"url":"https://sah.borca.ai/u/7c402c1b98"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_77338944702374b0bba5f42e8675e2f8"},{"public_id":"cl_8aa446d249c137bc48b1d644323aee80","status":"active","text":"AMN107 and BMS-354825 maintain similar improvements in potency for all imatinib-resistant mutants tested except T315I.","confidence":0.95,"contributors":[{"id":32,"public_id":"7c402c1b98","public_label":"뀨 (7c402c1b98)","roles":["extraction"],"url":"https://sah.borca.ai/u/7c402c1b98"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_8aa446d249c137bc48b1d644323aee80"},{"public_id":"cl_c8b5b655495d46737aa84e606c7fdc7d","status":"active","text":"The most common mechanism of acquired imatinib resistance is Bcr-Abl kinase domain mutations with decreased imatinib sensitivity.","confidence":0.9,"contributors":[{"id":32,"public_id":"7c402c1b98","public_label":"뀨 (7c402c1b98)","roles":["extraction"],"url":"https://sah.borca.ai/u/7c402c1b98"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_c8b5b655495d46737aa84e606c7fdc7d"}],"concepts":[{"public_id":"co_1715474f63d0336d68a8d0c22db4afd8","status":"active","name":"Bcr-Abl kinase domain mutations","description":"Mutations in the kinase domain of Bcr-Abl that reduce imatinib sensitivity and cause acquired resistance.","types":["mutation","resistance mechanism"],"aliases":[],"contributors":[{"id":32,"public_id":"7c402c1b98","public_label":"뀨 (7c402c1b98)","roles":["extraction"],"url":"https://sah.borca.ai/u/7c402c1b98"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_1715474f63d0336d68a8d0c22db4afd8"},{"public_id":"co_54245bbbf64712f93033854b3baa6510","status":"active","name":"imatinib-resistant mutants","description":"Bcr-Abl kinase domain mutants that show decreased sensitivity to imatinib and represent clinical isolates.","types":["mutant","clinical isolate"],"aliases":[],"contributors":[{"id":32,"public_id":"7c402c1b98","public_label":"뀨 (7c402c1b98)","roles":["extraction"],"url":"https://sah.borca.ai/u/7c402c1b98"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_54245bbbf64712f93033854b3baa6510"},{"public_id":"co_6db0391a5473b9f8d9eb49aec26a98fe","status":"active","name":"T315I","description":"A specific imatinib-resistant Bcr-Abl kinase domain mutant for which AMN107 and BMS-354825 do not maintain improved potency.","types":["mutant"],"aliases":[],"contributors":[{"id":32,"public_id":"7c402c1b98","public_label":"뀨 (7c402c1b98)","roles":["extraction"],"url":"https://sah.borca.ai/u/7c402c1b98"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_6db0391a5473b9f8d9eb49aec26a98fe"},{"public_id":"co_828b6e6e92d92fd48513d3fd3dc7b8b7","status":"active","name":"acquired imatinib resistance","description":"Resistance to imatinib that develops during treatment, commonly due to Bcr-Abl kinase domain mutations.","types":["phenomenon","resistance mechanism"],"aliases":[],"contributors":[{"id":32,"public_id":"7c402c1b98","public_label":"뀨 (7c402c1b98)","roles":["extraction"],"url":"https://sah.borca.ai/u/7c402c1b98"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_828b6e6e92d92fd48513d3fd3dc7b8b7"},{"public_id":"co_86d4edddaa71218f0c58aea090d5e95b","status":"active","name":"BMS-354825","description":"A highly potent dual Src/Abl inhibitor being evaluated in clinical trials for imatinib-resistant CML.","types":["drug","inhibitor"],"aliases":[],"contributors":[{"id":32,"public_id":"7c402c1b98","public_label":"뀨 (7c402c1b98)","roles":["extraction"],"url":"https://sah.borca.ai/u/7c402c1b98"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_86d4edddaa71218f0c58aea090d5e95b"},{"public_id":"co_887fd140ed27d7fd24eadb615f174c1d","status":"active","name":"imatinib","description":"A Bcr-Abl tyrosine kinase inhibitor used as a therapy for CML, against which resistance can develop.","types":["drug","inhibitor"],"aliases":[],"contributors":[{"id":32,"public_id":"7c402c1b98","public_label":"뀨 (7c402c1b98)","roles":["extraction"],"url":"https://sah.borca.ai/u/7c402c1b98"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_887fd140ed27d7fd24eadb615f174c1d"},{"public_id":"co_8b4d598dc7dc6629fa37e518b179b214","status":"active","name":"wild-type Bcr-Abl","description":"The unmutated form of the Bcr-Abl kinase domain used as a reference in potency comparisons.","types":["protein","reference"],"aliases":[],"contributors":[{"id":32,"public_id":"7c402c1b98","public_label":"뀨 (7c402c1b98)","roles":["extraction"],"url":"https://sah.borca.ai/u/7c402c1b98"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_8b4d598dc7dc6629fa37e518b179b214"},{"public_id":"co_ab974e8db4bb8478675db64672fa6b7e","status":"active","name":"imatinib-refractory CML","description":"Chronic myelogenous leukemia that does not respond to imatinib therapy, often due to resistance mutations.","types":["condition","disease state"],"aliases":[],"contributors":[{"id":32,"public_id":"7c402c1b98","public_label":"뀨 (7c402c1b98)","roles":["extraction"],"url":"https://sah.borca.ai/u/7c402c1b98"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_ab974e8db4bb8478675db64672fa6b7e"},{"public_id":"co_e4cafdf0d433cf8f9b7e9e273cb61a4f","status":"active","name":"AMN107","description":"An improved potency, selective Abl inhibitor being evaluated in clinical trials for imatinib-resistant CML.","types":["drug","inhibitor"],"aliases":[],"contributors":[{"id":32,"public_id":"7c402c1b98","public_label":"뀨 (7c402c1b98)","roles":["extraction"],"url":"https://sah.borca.ai/u/7c402c1b98"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_e4cafdf0d433cf8f9b7e9e273cb61a4f"}],"external_ids":{"DOI":"10.1158/0008-5472.CAN-05-0259","ArXiv":null,"PubMed":15930265,"PubMedCentral":null,"MAG":2097946794,"DBLP":null,"ACL":null},"open_access":{"is_open_access":true,"pdf_url":"https://aacr.figshare.com/articles/journal_contribution/Supplementary_Figure_1_from_i_In_vitro_i_Activity_of_Bcr-Abl_Inhibitors_AMN107_and_BMS-354825_against_Clinically_Relevant_Imatinib-Resistant_Abl_Kinase_Domain_Mutants/22363796/1/files/39808019.pdf","landing_url":"https://www.semanticscholar.org/paper/4a4ba81b5a8cab7d178b242d035ca904dd5fc518","source":"semantic_scholar","pdf_url_source":"semantic_scholar_open_access_pdf","license":"CCBY","status":"GREEN","reason":null},"reference_availability":{"status":"available","references_indexed":true,"full_text_available":false,"full_text_source":null,"count_basis":"semantic_scholar_metadata","extraction_status":"not_applicable","reason":null},"source":{"provider":"episteme2","base_corpus":"semantic_scholar_dump","freshness_mode":"unknown","basis":["semantic_scholar_metadata","postgres_metadata"],"limits":["paper metadata is based on indexed upstream scholarly datasets","claims and concepts are available only for extracted papers","absence of claims or concepts means no extracted graph data is available in this response"],"status":"available","degraded":false,"degraded_reasons":[],"diagnostics":{"status":"available","degraded":false,"degraded_reasons":[],"metadata_status":"available","graph_status":"available","abstract_status":"available"},"source_flags":5},"paper_id":636453,"paper_uid":"4e81a3b7-f220-4e06-9f77-88ce2f0454aa","canonical_identity":{"paper_id":636453,"paper_uid":"4e81a3b7-f220-4e06-9f77-88ce2f0454aa","identity_status":"available","lookup_basis":"semantic_scholar_external_id","compatibility_path":"corpus_id"},"url":"https://sah.borca.ai/papers/554884"}